Outlook Therapeutics (OTLK) Net Cash Flow: 2015-2020
Historic Net Cash Flow for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$11.4 million.
- Outlook Therapeutics' Net Cash Flow fell 89.93% to -$11.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $5.4 million, marking a year-over-year decrease of 13.94%. This contributed to the annual value of -$8.5 million for FY2024, which is 241.19% down from last year.
- As of Q3 2020, Outlook Therapeutics' Net Cash Flow stood at -$11.4 million, which was down 156.52% from $20.2 million recorded in Q2 2020.
- Over the past 5 years, Outlook Therapeutics' Net Cash Flow peaked at $20.2 million during Q2 2020, and registered a low of -$11.4 million during Q3 2020.
- Its 3-year average for Net Cash Flow is -$36,527, with a median of -$1.5 million in 2018.
- Within the past 5 years, the most significant YoY rise in Outlook Therapeutics' Net Cash Flow was 9,858.63% (2018), while the steepest drop was 430.94% (2018).
- Over the past 5 years, Outlook Therapeutics' Net Cash Flow (Quarterly) stood at -$273,352 in 2016, then spiked by 3,996.90% to $10.7 million in 2017, then tumbled by 113.98% to -$1.5 million in 2018, then tumbled by 348.55% to -$6.7 million in 2019, then crashed by 89.93% to -$11.4 million in 2020.
- Its Net Cash Flow was -$11.4 million in Q3 2020, compared to $20.2 million in Q2 2020 and $3.3 million in Q1 2020.